secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001628280-25-048248
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences Q3 revenue $83M, raises FY2025 guidance to $327-335M; launches AdvanceAD-Tx test
--------------------------------------------------------------------------------

- Revenue $83.0M (Q3 2025) vs $85.8M YoY; net loss $0.5M vs net income $2.3M.
- Total test reports 26,841; DecisionDx-Melanoma and TissueCypher each exceeded 10,000 tests in a quarter for first time.
- Full-year 2025 revenue guidance raised to $327-335M from $310-320M.
- Launched AdvanceAD-Tx, a GEP test to guide systemic treatment for moderate-to-severe atopic dermatitis.
- Non-dermatologic revenue up 67% YoY; adjusted EBITDA $9.2M vs $21.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000162828025048248/0001628280-25-048248-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000162828025048248/cstl-20251103.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-048248

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer